L-glutamine/Finding

One finding, on its own

A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.

Decreases numeric rating scale (NRS) pain intensity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“NRS scores were significantly lower in group G than in group P at weeks 4, 5 and 6 (p=0.049, p=0.019, p=0.032, respectively; Fig. 3B).”
Quoted verbatim from L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial..
Study

RCT
Participants

40
Dose

10 g orally three times a day throughout the chemoradiotherapy course
Population

Patients with untreated squamous cell carcinoma of the nasopharynx, oropharynx, hypopharynx or larynx receiving weekly cisplatin and docetaxel with 66-70 Gy radiation in both arms; strongest daily pain on a 0-10 NRS, reported at weeks 4, 5 and 6
L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial.2015PMID:25351453Industry fundedPermalink

Keep reading

To cite this finding: https://catalystproject.ai/e/01M454KZ57E6PV87C2A46THC0F